Edit
ITM Isotope Technologies Munich SE
https://itm-radiopharma.com/homeLast activity: 06.06.2024
Active
PASSION FOR PRECISION.
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.
ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information please visit: www.itm-radiopharma.com.
Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.
ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information please visit: www.itm-radiopharma.com.
Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines
Location: Germany, Bavaria, Garching bei München
Employees: 201-500
Total raised: $526.71M
Founded date: 2004
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.06.2024 | - | $204.57M | - |
| 06.05.2023 | - | $285.87M | Nextech In... |
| 28.03.2022 | - | $36.26M | - |
Mentions in press and media 15
| Date | Title | Description |
| 06.06.2024 | ITM Raises €188M in Funding | ITM, a Munich, Germany-based radiopharmaceutical biotech company, raised €188M in funding. The round was led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne. Led by CEO Stef... |
| 28.12.2023 | These are the 23 largest European funding rounds of 2023 | Read this article in: Over the last two decades, Europe’s startup ecosystem has transformed, evolving from an outsider to a global contender. The region hosts several prominent startup hubs, solidifying its position on the global tech stage... |
| 13.06.2023 | ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer | ITM Isotope Technologies Munich SE (ITM) opened its new production facility for Lutetium-177 for targeted radionuclide therapies against cancer. The new manufacturing plant in Neufahrn near Munich, Germany increases ITM's production capacit... |
| 06.05.2023 | ITM raises record sum of 255 million euros | Garching-based ITM has announced one of the largest private investment rounds in European biotechnology to date. With the sum of 255 million euros, the company plans to advance its radiopharmaceutical pipeline and expand its radioisotope pr... |
| 18.08.2022 | ITM Acquires a New Platform for the Development of Next-Generation Theranostics | • Technology platform for PET tracers strengthens ITM's radiodiagnostic portfolio • Additional assets potentially expand ITM's pipeline of novel targeted radionuclide therapeutics Garching / Munich, Germany – August 18, 2022 – ITM Isotope T... |
| 21.06.2022 | ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope | First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June 21, 2022 – An international collaboratio... |
| 28.03.2022 | ITM Isotope Technologies Munich Receives €33M Equity Funding | ITM Isotope Technologies Munich SE, a Munich, Germany-based radiopharmaceutical biotech company, closed an €33m equity funding. Backers included the Indigenous Critical Infrastructure Fund Canada (ICIF) and a private equity fund managed by ... |
| 03.02.2022 | ITM Announces Key Appointments to its U.S. Leadership Team | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced today the appointment of three key team members to lead the company’s planned expansion into the U.S. market. The team aims to advance ITM‘s ... |
| 25.01.2022 | ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE (NCT04919226), evaluating the company’s... |
| 19.01.2022 | ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the ASCO Gastrointestinal Cancers Symposium (AS... |
Show more